BidaskClub upgraded shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a sell rating to a hold rating in a research note released on Wednesday morning.
Several other equities research analysts have also weighed in on AMAG. ValuEngine upgraded AMAG Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Wednesday, October 3rd. Cantor Fitzgerald reiterated a hold rating and issued a $18.00 price objective (up from $17.00) on shares of AMAG Pharmaceuticals in a research note on Friday, August 3rd. B. Riley upped their price objective on AMAG Pharmaceuticals from $30.00 to $31.00 and gave the company a buy rating in a research note on Monday, August 6th. Jefferies Financial Group reiterated a hold rating and issued a $22.00 price objective on shares of AMAG Pharmaceuticals in a research note on Friday, August 3rd. Finally, Zacks Investment Research lowered AMAG Pharmaceuticals from a hold rating to a strong sell rating in a research note on Friday, October 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $23.07.
Shares of AMAG opened at $22.82 on Wednesday. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $26.10. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.95 and a current ratio of 2.06. The stock has a market cap of $790.46 million, a P/E ratio of -4.00 and a beta of 0.56.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative net margin of 36.87% and a negative return on equity of 2.77%. The company had revenue of $146.25 million during the quarter, compared to the consensus estimate of $156.26 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. Analysts anticipate that AMAG Pharmaceuticals will post -3.31 EPS for the current fiscal year.
In related news, CEO William K. Heiden sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the chief executive officer now directly owns 328,015 shares in the company, valued at approximately $8,200,375. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.00% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMAG. Northern Trust Corp grew its position in AMAG Pharmaceuticals by 1.0% during the 1st quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock worth $9,237,000 after acquiring an additional 4,468 shares during the last quarter. California Public Employees Retirement System lifted its holdings in AMAG Pharmaceuticals by 14.4% during the 1st quarter. California Public Employees Retirement System now owns 96,339 shares of the specialty pharmaceutical company’s stock worth $1,941,000 after buying an additional 12,098 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in AMAG Pharmaceuticals by 94.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 25,652 shares of the specialty pharmaceutical company’s stock worth $518,000 after buying an additional 12,491 shares in the last quarter. Sei Investments Co. lifted its holdings in AMAG Pharmaceuticals by 83.0% during the 1st quarter. Sei Investments Co. now owns 28,209 shares of the specialty pharmaceutical company’s stock worth $568,000 after buying an additional 12,793 shares in the last quarter. Finally, LPL Financial LLC acquired a new position in AMAG Pharmaceuticals during the 1st quarter worth $692,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Read More: Initial Public Offering (IPO)
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.